Ardelyx (ARDX) Earnings Date & Reports

Key Takeaways

• Total product revenue rose 19% year over year to $125.5 million, driven primarily by its lead product IBSRELA.
• IBSRELA revenue climbed 23% to $96.3 million, while XPHOZAH grew 7% to $29.2 million.
• The net loss narrowed to roughly $700,000, approaching breakeven, with $285.3 million in cash and short-term investments at quarter-end.
• Management reaffirmed full-year 2026 guidance for both products and for operating expenses.
• The ACCEL Phase III trial of IBSRELA in chronic idiopathic constipation (CIC) completed enrollment ahead of schedule, with results expected in the second half of 2027.
• Shares rose more than 9% in after-hours trading following the report.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these pages for additional insights.
• You can also explore Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.

Earnings Context and Why It Matters

Ardelyx's third-quarter update tests whether the company can convert strong demand for its two commercial products—IBSRELA and XPHOZAH—into durable revenue growth and, ultimately, profitability. The business has been navigating payer friction and prior authorization hurdles that slow new IBSRELA prescriptions, while absorbing higher operating costs tied to an expanded sales force and its first direct-to-consumer (DTC) advertising campaign. After lowering its full-year 2026 IBSRELA guidance earlier this year, management entered the quarter needing to demonstrate execution. These results offer a read on whether access initiatives are gaining traction and whether the company remains on track for its stated goal of profitability in 2027.

Reported Results

For the third quarter ended September 30, 2026, Ardelyx reported total product revenue of $125.5 million, up 19% from $105.5 million in the same period a year earlier. IBSRELA (tenapanor), approved for irritable bowel syndrome with constipation (IBS-C), generated $96.3 million, a 23% increase year over year. XPHOZAH (tenapanor), approved for hyperphosphatemia in adults with chronic kidney disease (CKD) on dialysis, contributed $29.2 million, up 7%.

On the bottom line, the company's net loss narrowed to approximately $700,000, compared with a loss of about $1 million a year earlier—effectively breakeven for the quarter. Research and development (R&D) expenses rose to $25.2 million from $18.1 million, reflecting investment in the ACCEL trial, while selling, general and administrative (SG&A) expenses increased to $93.9 million from $83.6 million. Ardelyx ended the quarter with $285.3 million in cash, equivalents, and short-term investments.

Management reaffirmed full-year 2026 guidance of $350 million to $370 million for IBSRELA and $110 million to $120 million for XPHOZAH, with operating expenses expected below $500 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking a single name like ARDX or surveying an entire sector, the AI Screener can help streamline your research and surface ideas aligned with your strategy.

Market Reaction and Investor Sentiment

Investors responded favorably to the report, with ARDX shares rising roughly 9.6% in after-hours trading to about $3.32 after closing the regular session near $3.03. The stock has been under pressure through much of the year, down approximately 48% year to date and more than half over the prior six months, leaving it toward the lower end of its 52-week range.

The positive move came despite total revenue landing slightly below some consensus estimates, which had projected around $128 million to $129 million. Instead, the market appeared to focus on the durability of IBSRELA demand, the sharply narrowed loss, a robust cash position, and management's decision to reaffirm full-year guidance. The after-hours reaction suggests investors weighed the long-term commercial trajectory and the approaching profitability milestone more heavily than the modest revenue shortfall.

Forward Outlook and Key Factors to Monitor

Following this report, the central question is whether Ardelyx can sustain IBSRELA's growth while managing access friction. The company has expanded its sales force, doubled its field reimbursement team, and launched its first DTC advertising campaign. Investors will be watching whether these initiatives translate into higher prescription fulfillment and new patient starts over the next several quarters.

On the pipeline front, the ACCEL Phase III trial of IBSRELA in CIC is now fully enrolled ahead of schedule, with top-line results expected in the second half of 2027. A positive readout would represent a meaningful potential expansion of the product's addressable market.

For XPHOZAH, the evolving dialysis reimbursement environment remains a key variable. Management has indicated it will wait until it has greater clarity on that landscape before reinstating a longer-term revenue framework for the product. Finally, cost discipline will be important: while the greater than 95% gross margin supports operating leverage, rising R&D and SG&A spending means expense management will help determine how quickly the company reaches its 2027 profitability target.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations